101214-22-6

Basic information

• Product Name: FMOC-GLU(OTBU)-OSU
• Synonyms: FMOC-GLUTAMIC ACID(OTBU)-OSU;FMOC-GLU(OTBU)-OSU;FMOC-GLU(OBUT)-OSU;FMOC-L-GLUTAMIC ACID GAMMA-T-BUTYL ESTER N-HYDROXYSUCCINIMIDE ESTER;FMOC-L-GLUTAMIC ACID-GAMMA-T-BUTYL-ALPHA-HYDROXYSUCCINIMIDE DIESTER;FMOC-L-GLUTAMIC ACID GAMMA-T-BUTYL-ALPHA-N-HYDROXYSUCCINIMIDE DI-ESTER;FMOC-L-GLUTAMIC ACID-GAMMA-T-BUTYL ESTER ALPHA-N-HYDROXYSUCCINIMIDE ESTER;NALPHA-9-Fluorenylmethoxycarbonyl-L-glutamic acid GAMMA- tert-butyl-ALPHA-
• CAS NO: 101214-22-6
• Molecular Formula: C28H30N2O8
• Molecular Weight: 522.55
• Product Categories: Amino Acid Derivatives;Amino Acids
• Mol File: 101214-22-6.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• Density: 1.34±0.1 g/cm3(Predicted)
• Storage Temp.: -15°C
• PKA: 9.94±0.46(Predicted)
• CAS DataBase Reference: FMOC-GLU(OTBU)-OSU(CAS DataBase Reference)
• NIST Chemistry Reference: FMOC-GLU(OTBU)-OSU(101214-22-6)
• EPA Substance Registry System: FMOC-GLU(OTBU)-OSU(101214-22-6)

Safety Data

• Hazardous Substances Data: 101214-22-6(Hazardous Substances Data)

Usage

Chemical Properties

White powder

Upstream product

• 6066-82-6 1-hydroxy-pyrrolidine-2,5-dione 
• 71989-18-9 Fmoc-Glu(OtBu)-OH 

Relevant articles and documents

Synthesis and structural characterization of triple-helical peptided which mimic the ligand binding site of the human macrophage scavenger receptor

A synthetic method for triple-helical peptides was developed. Peptides with and without glutamic acid a-thioester at their N-termini are prepared by the solid-phase method. These peptides are crosslinked at their N-termini one by one to generate trimeric peptides using the activation of the thioester group by silver ions. This method was applied to the synthesis of model peptides, which mimic the binding site of modified low density lipoprotein (LDL) in the human scavenger receptor (SR). These models possessed different spacers, which connect the peptide chains and the crosslinking site. CD and DSC analysis of the peptides revealed that spacer length has a critical effect on the stability of the triple helix.

ANTI-CD40 ANTIBODY DRUG CONJUGATES

Provided herein are anti-CD40 antibody drug conjugates comprising a radical of Formula (I), wherein R1, R2, and R3 are as defined herein. Further provided are anti-CD40 antibody drug conjugates of Formula (II), wherein Z, R, AA1, AA2, AA3, m, p, q, n, w, R1, R2, and R3 are as defined herein. Further provided are pharmaceutical compositions and kits thereof, and methods of using same.